These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 7521905)

  • 1. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
    J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
    J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
    Asakuma M; Yamamoto M; Wada M; Ryuge S; Katono K; Yokoba M; Fukui T; Takakura A; Otani S; Maki S; Igawa S; Yanaihara T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1529-36. PubMed ID: 22415148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer; 1998 Jun; 82(11):2166-72. PubMed ID: 9610696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
    Yanaihara T; Yokoba M; Onoda S; Yamamoto M; Ryuge S; Hagiri S; Katagiri M; Wada M; Mitsufuji H; Kubota M; Arai S; Kobayashi H; Yanase N; Abe T; Masuda N
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):419-27. PubMed ID: 16832665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Takada M; Kusunoki Y; Negoro S; Matsui K; Kudoh S; Takifuji N; Nakagawa K; Kishimoto S
    J Clin Oncol; 1992 Nov; 10(11):1775-80. PubMed ID: 1328551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
    Oshita F; Noda K; Nishiwaki Y; Fujita A; Kurita Y; Nakabayashi T; Tobise K; Abe S; Suzuki S; Hayashi I; Kawakami Y; Matsuda T; Tsuchiya S; Takahashi S; Tamura T; Saijo N
    J Clin Oncol; 1997 Jan; 15(1):304-9. PubMed ID: 8996157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
    Yamamoto N; Tamura T; Nishiwaki Y; Kurita Y; Kawakami Y; Abe S; Nakabayashi T; Suzuki S; Matsuda T; Hayashi I; Takahashi T; Saijo N
    Clin Cancer Res; 1997 Jul; 3(7):1087-92. PubMed ID: 9815787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies of irinotecan alone and in combination with cisplatin.
    Fukuoka M; Masuda N
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S105-11. PubMed ID: 8070018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
    Katakami N; Takada M; Negoro S; Ota K; Fujita J; Furuse K; Ariyoshi Y; Ikegami H; Fukuoka M
    Cancer; 1996 Jan; 77(1):63-70. PubMed ID: 8630941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
    Fujishiro M; Shinkai T; Fukuda M; Tamura T; Ohe Y; Kunitoh H; Nishiwaki Y; Sekine I; Fukuda H; Saijo N
    Jpn J Clin Oncol; 2000 Nov; 30(11):487-93. PubMed ID: 11155918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.